ABBISKO-B(02256): The first patient has been dosed in the clinical trial of the new pan-KRAS inhibitor ABSK211.
He Yu-B (02256) announced that its subsidiary, Shanghai He Yu Biomedical Technology Co., Ltd. ("He Yu Pharmaceutical"), has completed the first patient dosing in a Phase I clinical trial of its oral, highly potent, and broadly covering small molecule pan-KRAS inhibitor ABSK211 for the treatment of patients with advanced solid tumors carrying KRAS gene alterations.
ABBISKO-B (02256) announced that its subsidiary, Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Pharma), has reported that the Phase I clinical trial of its oral, high-potency, and broadly targeted small molecule pan-KRAS inhibitor ABSK211 for the treatment of patients with advanced solid tumors carrying KRAS gene alterations has completed dosing in the first patient.
Related Articles
BLACK SESAME (02533) released its interim results, reporting revenue of 458 million yuan, a year-on-year increase of 81.3%.
Earnings Report Preview | The customized AI chip model is undergoing a performance test. Can Broadcom Inc. (AVGO.US) Q3 earnings report meet the market's enormous expectations?
UNITEDENERGY GP (00467) announced its interim results, with profit attributable to shareholders reaching HK$953 million, a year-on-year increase of 28.7%.
BLACK SESAME (02533) released its interim results, reporting revenue of 458 million yuan, a year-on-year increase of 81.3%.
Earnings Report Preview | The customized AI chip model is undergoing a performance test. Can Broadcom Inc. (AVGO.US) Q3 earnings report meet the market's enormous expectations?
UNITEDENERGY GP (00467) announced its interim results, with profit attributable to shareholders reaching HK$953 million, a year-on-year increase of 28.7%.
RECOMMEND
